Equity Components [Axis]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Parent [Member]
Noncontrolling Interest [Member]
Business Combination [Axis]
CliniQuantum [Member]
Legal Entity [Axis]
VCT Israel [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Share Exchange Agreement [Member]
Investment, Name [Axis]
Gix Internet Ltd [Member]
Gix Media Ltd [Member]
Securities Exchange Agreement [Member]
Statistical Measurement [Axis]
Maximum [Member]
Prefunded Warrants [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Intangible Asset, Finite-Lived, Class [Axis]
In Process Research and Development [Member]
Internal Software [Member]
Customer Relations [Member]
Technology [Member]
Goodwill [Member]
Cortex Acquisition [Member]
Title and Position [Axis]
Gix Media [Member]
Share Purchase Agreement [Member]
Class of Stock [Axis]
Series J Preferred Stock [Member]
Metagramm Software Ltd. [Member]
Sale of Stock [Axis]
Private Placement [Member]
Minimum [Member]
Quantum X Labs Ltd [Member]
Warrant [Member]
Financing Agreement [Member]
Investment Company, Nonconsolidated Subsidiary [Axis]
CliniQuantum Ltd [Member]
Quantum Israel [Member]
Debt Instrument [Axis]
Short Term Bank Loan [Member]
Award Date [Axis]
July Ten Two Thousand Twenty Five [Member]
Quantum X Labs Inc [Member]
Convertible Loan June Facility [Member]
Short-Term Debt, Type [Axis]
Line of Credit [Member]
Gix Media Ltd One [Member]
Gix Media And Leumi [Member]
July 2025 Repayment and Financing Agreement [Member]
Loan Agreement [Member]
Related and Nonrelated Parties [Axis]
Viewbix Israel [Member]
2023 Warrant [Member]
June 2024 Facility Agreement Warrants [Member]
June 2024 Convertible Stock [Member]
June 2024 Lead Lender Fee Warrants [Member]
Class of Warrant or Right [Axis]
June 2024 Lead Lender Warrant [Member]
First July 2024 Facility Agreement [Member]
First July 2024 Convertible Stock [Member]
Lender Name [Axis]
First July 2024 Lender [Member]
Second July 2024 Facility Agreement [Member]
Second July 2024 Convertible Stock [Member]
Second July 2024 Lenders [Member]
Derivative Instrument [Axis]
Earnout Liability [Member]
Embedded Derivative Financial Instruments [Member]
June 2024 Facility Agreements [Member]
First July 2024 Facility Agreements [Member]
Second July 2024 Facility Agreements [Member]
Consultant [Member]
PIPE Warrants [Member]
Investor [Member]
July Twenty Twenty Five Private Placement [Member]
Securities Purchase Agreement [Member]
2026 Private Placement [Member]
Plan Name [Axis]
2023 Stock Incentive Plan [Member]
Class J Warrants [Member]
Class K Warrants [Member]
June 2024 Facility Agreement Warrants [Member]
2024 PIPE Warrants [Member]
2025 July Private Placement Prefunded Warrants [Member]
2025 July Private Placement Common Warrants [Member]
Twenty Twenty Six July Private Placement Common Warrants [Member]
Quantum Israel Acquisition Pre Funded Warrants [Member]
Segments [Axis]
Search Segment [Member]
Quantum Technology Segment [Member]
Adjustments and Eliminations [Member]
Consolidation Items [Axis]
Intersegment Eliminations [Member]
2026 PIPE Warrants [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
Statement of Financial Position [Abstract]
ASSETS
CURRENT ASSETS
Cash and cash equivalents
Restricted deposits
Accounts receivable
Related parties
Other current assets
Total current assets
NON-CURRENT ASSETS
Deferred taxes
Property and equipment, net
Investment in equity securities
Intangible assets, net
Goodwill
Investments accounted for using the equity method
Total non-current assets
Total assets
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable
Government authorities
Earn-out payable
Short-term loans
Current maturities of long-term loans
Short-term convertible loans
Related parties
Other payables
Total current liabilities
NON-CURRENT LIABILITIES
Long-term loans, net of current maturities
Deferred taxes
Earn-out liability
Total non-current liabilities
Commitments and Contingencies
SHAREHOLDERS’ EQUITY
Common stock of $0.0001 par value - Authorized: 490,000,000 shares; Issued and outstanding: 18,829,198 and 10,670,392 shares as of June 30, 2026, and December 31, 2025, respectively.
Additional paid-in capital
Accumulated deficit
Equity attributed to shareholders of Quantum X Labs Inc.
Non-controlling interests
Total equity
Total liabilities and shareholders’ equity
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Revenues
Costs and Expenses:
Traffic-acquisition and related costs
Research and development
Selling and marketing
General and administrative
Depreciation and amortization
Other expenses, net
Operating loss
Gain from deconsolidation of CliniQuantum
Financial expenses, net
Income (loss) from continuing operations, before taxes
Tax benefit
Net income (loss) from continuing operations
Net loss from discontinued operations
Net income (loss)
Less: net loss attributable to non-controlling interests
Net income (loss) attributable to shareholders of Quantum X Labs Inc.
Net income (loss) from continuing operations attributable to:
Shareholders of Quantum X Labs Inc.
Non-controlling interests
Net loss from continuing operations
Net loss from discontinued operations attributable to:
Shareholders of Quantum X Labs Inc.
Non-controlling interests
Net loss from discontinued operations
Net income (loss) per share from continuing operations attributed to shareholders:
Basic
Diluted
Net loss per share from discontinued operations - Basic attributed to shareholders
Net loss per share from discontinued operations - Diluted attributed to shareholders
Total net income (loss) per share attributed to shareholders:
Basic
Diluted
Weighted average number of shares (*):
Basic
Diluted
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Net income (loss)
Issuance of shares and warrants in connection with a private placement (see note 10.D)
Issuance of shares and warrants in connection with a private placement (see note 10.D), shares
Issuance of shares in connection with acquisition of a subsidiary (see note 6.B)
Issuance of shares in connection with acquisition of a subsidiary (see note 6.B), shares
Deconsolidation of subsidiary upon loss of control (see note 6.D)
Exercise of warrants (see notes 7.D, 7.E, 7.F, 10.B)
Exercise of warrants (see notes 7.D, 7.E, 7.F, 10.B), shares
Shares issued in connection with the Reverse Stock Split (see note 10.G)
Shares issued in connection with the Reverse Stock Split (see note 10.G), shares
Issuance of shares and warrants in connection with conversion of loans (see notes 7.D, 7.E, 7.F)
Issuance of shares and warrants in connection with conversion of loans (see notes 7.D, 7.E, 7.F), shares
Redeem of loan to parent company (see note 4)
Share-based compensation
Share-based compensation, shares
Balance
Balance, shares
Statement of Cash Flows [Abstract]
Cash flows from Operating Activities of Continuing Operations
Less: net loss from discontinued operations
Net income (loss) from continuing operations
Adjustments to reconcile net loss from continuing operations to net cash provided by operating activities:
Share-based compensation
Deferred taxes
Accrued interest, net
Interest income
Amortization of loan discounts
Change in the fair value of financial assets at fair value through profit or loss (see note 8)
Amortization of deferred debt issuance costs (see notes 7.D. 7.E, 7.F)
Gain arising from deconsolidation of a subsidiary upon loss of control (see note 6.D)
Changes in assets and liabilities items:
Decrease in accounts receivable
Increase in other current assets
Increase in related parties
Increase (decrease) in accounts payable
Decrease (increase) in other payables
Net cash used in operating activities from continuing operations
Cash flows from Investing Activities of Continuing Operations
Purchase of property and equipment
Deconsolidation of a subsidiary upon loss of control (see appendix B and note 6.D)
Net cash from acquisition of subsidiaries (see appendix A and notes 6.B, 6.C)
Net cash provided by (used in) investing activities from continuing operations
Cash flows from Financing Activities of Continuing Operations
Receipt of short-term convertible loans
Repayment of short-term convertible loans
Receipt of short-term bank loans
Repayment of short-term bank loans
Repayment of long-term bank loans
Change in loan to former parent company
Proceeds from issuance of shares and warrants in connection with the 2026 Private Placement (see note 10.D)
Proceeds from exercise of warrants
Net cash provided by financing activities from continuing operations
Cash flows of Discontinued Operations
Net cash used in operating activities from discontinued operations
Net cash used in investing activities from discontinued operations
Net cash provided by financing activities from discontinued operations
Net cash used in discontinued operations
Increase in cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash at beginning of period
Cash and cash equivalents and restricted cash at end of period
Supplemental Disclosure of Cash Flow Activities:
Cash paid during the period
Taxes paid
Interest paid
Total cash paid during the period
Substantial non-cash activities:
Redeem of loan to parent company
Conversion of loans into shares and warrants
Issuance of warrants in connection with the 2026 Private Placement (see note 10.D)
Classification of Earn-out liability to Earn-out payable (see note 8)
Restructuring Cost [Table]
Restructuring Cost and Reserve [Line Items]
Consolidation of Quantum Israel (see note 6.C):
Net working capital other than cash and restricted deposits
Property and equipment
In-process research and development, net of deferred taxes
Total consideration
Net cash acquired
Deconsolidation of subsidiary upon loss of control (see note 6.D):
Net working capital other than cash and restricted deposits
Recognition of investment accounted for using the equity method
Non-controlling interests
Gain arising from deconsolidation upon loss of control
Net cash deconsolidated upon loss of control
Accounting Policies [Abstract]
GENERAL
SIGNIFICANT ACCOUNTING POLICIES
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS
Related Party Transactions [Abstract]
LOAN TO FORMER PARENT COMPANY
Intangible Asset, Goodwill and Other [Abstract]
GOODWILL AND INTANGIBLE ASSETS, NET
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]
BUSINESS COMBINATION
Receivables [Abstract]
LOANS
Investments, All Other Investments [Abstract]
FINANCIAL INSTRUMENTS AT FAIR VALUE
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES
Equity [Abstract]
SHAREHOLDERS’ EQUITY
Earnings Per Share [Abstract]
EARNING (LOSS) PER SHARE
Segment Reporting [Abstract]
SEGMENT REPORTING
Subsequent Events [Abstract]
SUBSEQUENT EVENTS
Unaudited Interim Financial Statements
Principles of Consolidation
Use of estimates
Significant Accounting Policies
Recent Accounting Pronouncements
SCHEDULE OF DISCONTINUED OPERATIONS
SCHEDULE OF GOODWILL AND INTANGIBLE ASSETS
Business Combination [Table]
Business Combination [Line Items]
SCHEDULE OF FAIR VALUE OF ASSETS AND LIABILITIES
SCHEDULE OF COMPOSITION OF BALANCE OF GROUP’S LOANS
SCHEDULE OF FINANCIAL INSTRUMENTS
SCHEDULE OF OUTSTANDING WARRANTS
SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE
SCHEDULE OF SEGMENTS REVENUES AND OPERATING RESULTS
SCHEDULE OF RECONCILIATION BETWEEN SEGMENTS OPERATING RESULTS
Property, Plant, and Equipment [Table]
Property, Plant, and Equipment [Line Items]
Proceeds from sale
Ownership percentage
Related party transaction description
Reverse stock split
Business acquired percentage
Business consideration
Number of stock issued
Issued and outstanding share capital, percentage
Goodwill impairment loss
Interest expense debt
Gross proceeds
Proceeds from short-term debt
Warrant exercises
Operating loss
Bank loan
Revenues
Traffic-acquisition and related costs
Research and development
Selling and marketing
General and administrative
Depreciation and amortization
Impairment of intangible assets and goodwill
Operating loss
Financial income, net
Loss from discontinued operations before taxes
Income tax benefit
Net loss from discontinued operations
Recognized an impairment loss
Intangible assets
Waiver of loan to parent company
Interest income
Intangible Asset, Finite-Lived [Table]
Intangible Asset, Finite-Lived [Line Items]
Cost, beginning balance
Consolidation of Metagramm (note 6.B)
Cost, ending balance
Accumulated amortization, beginning balance
Amortization recognized during the period
Accumulated amortization, ending balance
Amortized cost
Cash and cash equivalents and restricted deposits
Other current assets
Net working capital other than cash and restricted deposits
Property and equipment
Goodwill arising from the acquisition
Technology, net of deferred taxes
Customer Relations, net of deferred taxes
Total cost of the acquisition
Earn-out liability arising from the acquisition
Total liabilities
Consideration paid in Company’s shares and pre-funded warrants
Contingent consideration to be paid in Earn-Out Securities
Total Consideration
Non-controlling interests
Business acquisition description of acquired entity
Debt instrument face amount
Line of credit maximum
Long term debt
Business consideration, cash
Shares issued, value
Shares issued
Cash earn-out payments
Estimated useful lives
Number of warrants issued
Number of shares issued
Acquired percentage
Exercise price
Contingent consideration
Fair value of investments
Gain from deconsolidation
Accounts and Financing Receivables [Table]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Short-term bank loans
Debt instrument description
Long-term loan
Short-term convertible loans – June 2024 Facility Agreement – Quantum X Labs Inc.
Debt instrument description
Bank loan
Financing Receivable, Modified [Table]
Financing Receivable, Modified [Line Items]
Line of credit
Debt instrument, interest rate, stated percentage
Debt instrument frequency
Long term loan maturity
Repayment of short term debt
Loan amount repaid
Short-term loan
Loans
Debt instrument description
Aggregate amount
Warrants to purchase shares
Warrants expire date
Line of credit facility, outstanding debt owed
Line of credit facility, expiration period
Line of credit facility, withdrawn amount description
Accrued interest percentage
Credit facility amount
Number of shares new isues
Conversion price
Warrants term
Shares issued
Warrants exercise amount
Deferred debt issuance costs
Warrants exercise amount
Line of credit additional borrowing amount
Warrants granted
Warrants exercised
Proceeds from warrant exercises
Repurchase of warrants
Converted into shares and warrants
Line of credit facility, remaining borrowing capacity
Line of credit facility, financing transaction
Line of credit facility, one-time fee, percentage
Deferred debt issuance costs
Received loan
Deferred debt issuance costs
Offsetting Assets [Table]
Offsetting Assets [Line Items]
Beginning balance
Earn-out liability recorded in connection with Metagramm Acquisition (see note 6.B)
Net changes at fair value recognized through profit or loss
Embedded derivatives converted to equity
Earn-out payable amounts upon achieving financing milestone in connection with Metagramm Acquisition (see note 6.B)
Ending balance
Loss Contingencies [Table]
Loss Contingencies [Line Items]
Restricted deposit
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants
Warrant Term
Warrants
Exercisable
Warrants outstanding as of January 1, 2025
Warrants outstanding as of June 30, 2025
Warrants outstanding beginning
Warrants granted
Warrants exercised
Warrants outstanding ending
Credit facility amount converted
Common stock issued upon conversion
Share-based compensation
Offering price per share
Warrant purchase
Exercise price
Actual and documented fees
Cash fee
Number of shares issued
Cash placement fee percentage
Legal fees and disbursements
Issuance costs
Cash fee
Repayment of debt
Reverse stock split conversion
Shares, granted
Outstanding capital stock percent
Common stock, capital shares reserved for future issuance
Net income (loss) attributable to Quantum X Labs Inc shareholders
Interest expenses on convertible loans
Adjusted net income (loss)
Weighted average shares
Warrants and converted loans
Dilutive potential common shares
Adjusted weighted average shares
Basic earnings (loss) per share attributable to Quantum X Labs Inc shareholders
Diluted earnings (loss) per share attributable to Quantum X Labs Inc shareholders
Segment Reporting [Table]
Segment Reporting [Line Items]
Revenues from external customers
Traffic-acquisition and related costs
Research and development expenses
Sales and marketing expenses
General and administrative expenses
Depreciation and amortization
Other expenses, net
Segment operating income (loss)
Gain from deconsolidation of a subsidiary
Financial (expenses) income, net
Segment income (loss), before income taxes
Depreciation and amortization expenses not attributable to segments
Goodwill Impairment
Total
Number of reportable segment
Subsequent Event [Table]
Subsequent Event [Line Items]
Stock issued during period shares, issued for services
Debt converted amount
Common stock issued upon conversion
Warrant term
Related parties advances current.
Government authorities liabilities current.
Earnout payable amounts.
Convertible debt short term.
Related parties debt current.
Earnout liability.
Issuance of shares and warrants in connection with private placement.
Stock issued during period value exercise of warrants
Issuance of shares and warrants in connection with private placement shares.
Stock issued during period shares exercise of warrants
Stock issued during period value reverse stock splits.
Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.
Amount after tax of income (loss) from continuing operations attributable to the parent..
Accrued interest, net.
Increase (Decrease) in other payable.
Receipt of short term bank loan
Repayment of short-term bank loans.
Change in loan to former parent company.
Cash paid and received during period abstract
Cash paid during period.
Issuance of warrants in connection with 2026 private placement.
Classification of earnout liability to other payables.
Conversion of loans into shares and warrants.
Redeem of loan to parent company.
Quantum Israel [Member]
Business combination recognized identifiable assets acquired and liabilities assumed property and equipment.
Business combination customer relations net of deferred taxes.
Business combination In-process research and development, net of deferred taxes.
Business combination recognized identifiable assets acquired and liabilities consolidation of subsidiary.
CliniQuantum [Member]
Consolidation of quantum Israel.
Business combination recognized identifiable assets acquired and liabilities assumed net working capital other than cash.
Business combination recognized identifiable assets acquired and liabilities consideration paid in companys shares and prefunded warrants.
Deconsolidation of subsidiary upon loss of control [Abstract]
Deconsolidation net working capital other than cash and restricted deposits
Deconsolidation net cash deconsolidated upon loss of control
Deconsolidation recognition of investment accounted for using the equity method.
Deconsolidation gain arising from deconsolidation upon loss of control.
Deconsolidation non-controlling interests.
VCT Israel [Member]
Share Exchange Agreement [Member]
Gix Internet Ltd [Member]
Gix Media Ltd [Member]
Securities Exchange Agreement [Member]
Issued and outstanding share capital, percentage
Prefunded Warrants [Member]
Unaudited Interim Financial Information [Policy Text Block]
Significant Accounting Policies [Policy Text Block]
Disposal group including discontinued operation traffic acquisition and related costs.
Disposal group including discontinued operation research and development.
Disposal group including discontinued operation selling and marketing.
Disposal group including discontinued operation impairment of intangible assets and goodwill.
Disposal group including discontinued operation financial income net.
Waiver of loan to parent company.
Internal Software [Member]
Customer Relations [Member]
Technology [Member]
Cortex Acquisition [Member]
Gix Media [Member]
Share Purchase Agreement [Member]
Series J Preferred Stock [Member]
Metagramm Software Ltd. [Member]
Business combination technology net of deferred taxes.
Business combination earnout liability arising from acquisition.
Acquisition cost.
Quantum X Labs Ltd [Member]
Net working capital other than cash and restricted deposits.
Consideration paid in companys shares and prefunded warrants.
Contingent consideration transferred in companys prefunded warrants.
Financing Agreement [Member]
Short Term Bank Loan [Member]
July Ten Two Thousand Twenty Five [Member]
Quantum X Labs Inc [Member]
Convertible Loan June Facility [Member]
Gix Media Ltd One [Member]
Current maturities of long term loan.
Gix Media And Leumi Member.
July 2025 Repayment and Financing Agreement [Member]
Loan Agreement Member.
View bixIsrael Member.
2023 Warrant [Member]
June 2024 Facility Agreement Warrants [Member]
June 2024 Convertible Stock [Member]
June 2024 Lead Lender Fee Warrants [Member]
June 2024 Lead Lender Warrant [Member]
Warrants exercise amount
First July 2024 Facility Agreement [Member]
Line of credit facility, financing transaction
First July 2024 Convertible Stock [Member]
First July 2024 Lender [Member]
Line of credit facility, one-time fee, percentage
Deferred finance costs net including upfront fee.
Proceeds from loans received.
Second July 2024 Facility Agreement [Member]
Second July 2024 Convertible Stock [Member]
Second July 2024 Lenders [Member]
Earnout Liability [Member]
Earn-out payable amounts upon achieving financing milestone in connection with Metagramm Acquisition.
Earn-out liability recorded in connection with Metagramm Acquisition.
Line of credit additional borrowing amount.
June 2024 Facility Agreements [Member]
First July 2024 Facility Agreements [Member]
Second July 2024 Facility Agreements [Member]
Consultant [Member]
PIPE Warrants [Member]
Cash placement fee percentage.
Securities Purchase Agreement [Member]
2026 Private Placement [Member]
Class J Warrants Member.
Warrants outstanding term
Share based compensation arrangement by share based payment award non option equity instruments exercisable.
Class K Warrants Member.
June 2024 Facility Agreement Warrants [Member]
2024 PIPE Warrants [Member]
2025 July Private Placement Prefunded Warrants [Member]
2025 July Private Placement Common Warrants [Member]
Twenty Twenty Six July Private Placement Common Warrants [Member]
Quantum Israel Acquisition Pre Funded Warrants [Member]
2023 Stock Incentive Plan [Member]
Outstanding capital stock percent.
Interest expenses on convertible loans.
June 2024 Lead Lender Warrant One [Member]
Search Segment [Member]
Quantum Technology Segment [Member]
Adjustments and Eliminations [Member]
Total Operating Segments [Member]
Business combination acquisition related cost.
Research and development expenses.
Selling and marketing expenses.
General and administrative expenses.
Depreciation and amortization expenses.
Financial Income (Expenses) Net.
Gain loss on deconsolidation of subsidiary.
Deconsolidation [Member]
Sale of stock percentage of ownership aquired.
CliniQuantum Ltd [Member]
Stock issued during period redeem of loan to parent company.
2026 PIPE Warrants [Member]
2026 PIPE Warrants [Member]
June 2024 Facility Agreement Warrants [Member] [Default Label]
Assets, Current
Assets, Noncurrent
Assets
RelatedPartiesDebtCurrent
Liabilities, Current
Deferred Income Tax Liabilities, Net
Liabilities, Noncurrent
Equity, Attributable to Parent
Equity, Including Portion Attributable to Noncontrolling Interest
Liabilities and Equity
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest
IncomeLossFromContinuingOperationsNetOfTaxAttributableToParent
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToParent
Shares, Outstanding
Noncontrolling Interest, Decrease from Deconsolidation
Share-Based Payment Arrangement, Noncash Expense
Deferred Income Taxes and Tax Credits
GainLossOnAccruedInterestNet
Interest Income, Operating
Gain (Loss) on Securitization of Financial Assets
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Other Current Assets
Increase (Decrease) in Due from Related Parties, Current
Cash Provided by (Used in) Operating Activity, Continuing Operation
Payments to Acquire Property, Plant, and Equipment
Cash Divested from Deconsolidation
Cash Provided by (Used in) Investing Activity, Continuing Operation
Repayments of Other Short-Term Debt
RepaymentOfShorttermBankLoans
Repayments of Long-Term Debt
Cash Provided by (Used in) Financing Activity, Continuing Operation
Cash Provided by (Used in) Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeconsolidationWorkingCapitalOtherThanCashNet
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeconsolidationNoncontrollingInterests
Equity [Text Block]
Disposal Group, Including Discontinued Operation, Revenue
DisposalGroupIncludingDiscontinuedOperationTrafficAcquisitionAndRelatedCosts
DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment
DisposalGroupIncludingDiscontinuedOperationSellingAndMarketing
Disposal Group, Including Discontinued Operation, General and Administrative Expense
Disposal Group, Including Discontinued Operation, Depreciation and Amortization
Disposal Group, Including Discontinued Operation, Operating Income (Loss)
Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax
Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period
Intangible Asset, Finite-Lived, after Accumulated Amortization
Intangible Asset, Finite-Lived, Accumulated Amortization
Intangible Asset, Including Goodwill, after Accumulated Amortization
Business Combination, Recognized Asset Acquired, Other Asset, Current
NetWorkingCapitalOtherThanCashAndRestrictedDeposits
Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment
Business Combination, Recognized Asset Acquired, Asset
Business Combination, Recognized Liability Assumed, Liability
ConsiderationPaidInCompanysSharesAndPrefundedWarrants
ContingentConsiderationTransferredInCompanysPrefundedWarrants
AcquisitionCost
Notes Payable to Bank, Current
Debt Instrument, Description
ClassOfWarrantOrRightExerciseAmountOfWarrants
DeferredFinanceCostsNetIncludingUpfrontFee
Debt Issuance Costs, Gross, Current
Embedded Derivative, Fair Value of Embedded Derivative Liability
Embedded Derivative, Gain (Loss) on Embedded Derivative, Net
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
WarrantGrantedShares
WarrantExercisesShares
Employee Benefits and Share-Based Compensation
Noninterest Expense Commission Expense
BusinessCombinationAcquisitionRelatedCost
DepreciationAndAmortizationExpenses
Other Operating Income (Expense), Net
Intangible Asset, Including Goodwill, Impairment Loss
Stock Issued During Period, Shares, Conversion of Units